Mesoblast Limited (MESO) vs Trevi Therapeutics, Inc. (TRVI)
- Mesoblast Limited MESO 13.28 −4.80%
- Trevi Therapeutics, Inc. TRVI 11.87 −1.98%
Mesoblast Limited and Trevi Therapeutics, Inc. are both Biotechnology companies. Mesoblast Limited and Trevi Therapeutics, Inc. are of similar size ($1.8B and $1.7B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.7%) and the lower return on invested capital (−1,412.1% vs 0.00%). Across the 13 metrics below, Trevi Therapeutics, Inc. leads on 7 and Mesoblast Limited on 6.
Valuation
Profitability
| Metric | MESO | TRVI | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 0.00% | 65.16% |
| Operating margin | (826.28%) | 0.00% | 0.00% |
| Net margin | (1,091.71%) | 0.00% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | 0.00% | (19.66%) | (56.36%) |
| Return on assets | 0.00% | (18.97%) | (48.04%) |
| Return on invested capital | 0.00% | (1,412.11%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack